Term
Bethanecol
1.Drug Classification/MOA
2.Clinical Application
3.Actions
4. Caution |
|
Definition
1.Direct muscarinic agonist
2. -postoperative/neurogenic ileus
-urinary retention
3. activates bowel and bladder smooth muscle
4. caution: COPD, asthma, peptic ulcers
|
|
|
Term
Carbachol
1. Drug Classification/MOA
2. Clinical Applications
3. Special Notes
4. Caution |
|
Definition
1. direct muscarinic agonist
2. -glaucoma
-pupillary contraction
-relief of intraocular pressure
3. CARBon copy of ACh
4. Caution: COPD, asthma, peptic ulcers |
|
|
Term
Pilocarpine
1. Drug Classification/MOA
2. Clinical applications
3. Action
4. Special notes
5. Caution
|
|
Definition
1. Direct muscarinic agonist
2. Glaucoma emergencies
-stimulates sweat, tears, saliva
3. contracts ciliary muscle of the eye
-contracts pupillary sphincter
4. resistant to AChE
5. caution: COPD, asthma, peptic ulcers
|
|
|
Term
Neostigmine
1. drug classification/MOA
2. clinical application
3. Special Notes
4. Caution |
|
Definition
1. Anti-cholinesterase (indirect muscarinic agonist)
2.-reversal of paralytics post-op (NMJ block)
-post-op/neurogenic ileus
-urinary retention
-myasthenia gravis
3. NO CNS PENETRATION
4. Caution: COPD, asthma, peptic ulcers
|
|
|
Term
Pyridostigmine
1. Drug class/MOA
2. clinical application
3. Special Notes
4. Caution |
|
Definition
1. anti-AChE (indirect muscarinic agonist)
2. Myasthenia Gravis
3. -Long acting
-NO CNS PENETRATION
4. Caution: COPD, asthma, peptic ulcers |
|
|
Term
Edrophonium
1. Drug Class/MOA
2. Clinical application
3. Special notes
4. Caution
|
|
Definition
1. Anti-AChE (indirect muscarinic agonist)
2. Diagnosis of myasthenia gravis
3.-Tensilon Test
-extremely short acting
4. Caution: COPD, asthma, peptic ulcers |
|
|
Term
Physostigmine
1. drug class/MOA
2. clinical applications
3. Special Notes
4. Caution |
|
Definition
1. Anti-AChE (indirect muscarinic agonist)
2. -glaucoma
-atropine overdose
3. physostigmine phyxes atropine OD
4. caution: COPD, asthma, peptic ulcers |
|
|
Term
Organophosphate Poisoning
1. mechanism of action
2. symptoms
3. treatment
4. special notes |
|
Definition
1. irreversible inhibitors of AChE
2. DUMBBELSS
diarrhea, urination, miosis, bronchospasm, bradycardia, excite skeletal muscle, lacrimation, sweating, salivation
3. Atropine (anti-muscarinic)
with Pralidoxime (regenerates AChE)
4. Farmers using insecticides (Parathion)
|
|
|
Term
Atropine
1. MOA
2. Action
3.Toxicity
4. Cautions |
|
Definition
1. muscarinic antagonist
2. dilates pupil, cycloplegia
decreases airway secretions
decrease gut motility
decrease bladder contraction
3. hyperthermia, tachycardia, xerostomia, dry flushed skin, constipation, delirium
4. Elderly- can cause narrow glaucoma
BPH- can cause urinary retention
Infants- hyperthermia
|
|
|
Term
Benztropine
1. Drug Class/MOA
2. Organ system
3. Clinical Application
4. Special notes |
|
Definition
1. muscarinic antagonist
2. CNS
3. Parkinson's Disease
4. Park my Benz
|
|
|
Term
Scopolamine
1. Drug class/MOA
2. organ system it affects
3. Clinical Applications |
|
Definition
1. muscarinic antagonist
2. CNS
3. Motion sickness, end of life care |
|
|
Term
Ipratropium
1. Drug Class/MOA
2. Organ system it affects
3. Clinical Applications
4. Special notes |
|
Definition
1. muscarinic antagonist
2. CNS
3. Asthma, COPD
4. IPray I can breathe soon. |
|
|
Term
Oxybutinin, Tolteridine, Trospium, Darifenacin/Solifenacin
1. MOA
2. Organ System it affects
3. Clinical Applications |
|
Definition
1. muscarinic antagonist
2. genitourinary
3. urge incontinence/mild cystitis |
|
|
Term
Glycopyrrolate
1. MOA
2. Organ System it affects
3. Clinical Applications |
|
Definition
1. muscarinic antagonist
2. genitourinary, respiratory
3. -anesthesiology- reduce airway secretions
-reduce urinary urgency |
|
|
Term
Methscopolamine, Propantheline
1. Drug Class/MOA
2. Organ System it Affects
3. Clinical Applications |
|
Definition
1. muscarinic antagonist
2. Gastrointestinal
3. peptic ulcer treatment |
|
|
Term
Hexamethonium
1. Drug Class/MOA
2. Actions
3. Clinical Application
4. Toxicity
5. Special Notes |
|
Definition
1. nicotinic receptor antagonist
2. blocks sympathetic and parasympathetic
(depends on tone of the organ)
-decreased BP
-increased HR
-decreased CO
-dereased GI motility
-mydriatic pupils
-oliguria
3. experimental models to prevent vagal reflexes to BP change
4. severe orthostatic hypotension, blurry vision, constipation, sexual dysfunction
5. Put a hex on smokers to help them quit |
|
|
Term
Epinephrine
-class
-receptors
-actions/applications
-special notes |
|
Definition
-direct sympathomimetic
-alpha 1, 2 beta 1,2
(low doses- beta 2 high doses-alpha 1)
-Anaphylactic Shock, asthma, hypotension
- large dose + alpha blocker lowers BP (beta 2 effect unopposed by alpha) (caution in BPH patients) |
|
|
Term
Norepinephrine
-receptors
-applications
-special notes |
|
Definition
direct sympathomimetic
-alpha 1, alpha 2 > beta 1
-Septic shock (hypotension)
-reflex bradtcardia
|
|
|
Term
Isoproterenol
-receptors
-applications
-special notes |
|
Definition
direct sympathomimetic
-beta 1= beta 2
-AV Block, lowers BP
-rarely used clinically
-reflex tachycardia |
|
|
Term
Dopamine
-receptors
-applications
-special notes |
|
Definition
-direct sympathomimetic
-D1=D2 (inotropic, chronotropic on the heart) > Beta > Alpha
-Co administer with norepinephrine in septic shock to protect renal perfusion
- in vivo doesn't help kidney blood flow |
|
|
Term
Dobutamine
-receptors
-applications |
|
Definition
direct sympathomimetic
-Beta 1 > Beta 2 (ino and chronotropic)
-heart failure, cardiac stress test ( increases O2 demand) |
|
|
Term
Phenylephrine
-receptors
-applications |
|
Definition
direct sympathomimetic
-alpha 1 > alpha 2
-Nasal decongestion, epistaxis, causes mydriasis |
|
|
Term
Metaproterenol, Albuterol, Sametrerol
-receptors
-actions
-applications
-special notes |
|
Definition
Direct sympathomimetics
-Selective Beta 2 >> Beta 1
-relax bronchial, vascular smooth muscle
-Acute Asthma- metaproterenol, albuterol
-Asthma long term - salmeterol
-reflex tachycardia
|
|
|
Term
Terbutaline, Ritodrine
-receptors
-Applications |
|
Definition
direct sympathomimetics
-Beta 2
-Reduce premature uterine contractions |
|
|
Term
Amphetamine, Tyramine
-Drug class
-Actions
-Applications |
|
Definition
-Indirect sympathomimetic
-Increases NE release at synapse
-Narcolepsy, ADD, obesity |
|
|
Term
Ephedrine
-Class
-MOA
-Applications |
|
Definition
-indirect sympathomimetic
-Increases release of stored catecholamines
-Nasal decongestion, urinary incontinence, hypotension |
|
|
Term
Cocaine
-Class
-MOA
-Applications |
|
Definition
-indirect sympathomimetic
-inhibits reuptake of NE at synapse
-Vasoconstriction (ENT) and local anesthetic |
|
|
Term
Clonidine,α-Methyldopa
Class
MOA
Applications
Special Notes
|
|
Definition
-sympathoplegic
α-2 agonists in CNS (stimulate autoreceptors)
-Hypertension-->renal dz and pregnancy
-frequent dosing, rebound hypertension if dose missed |
|
|
Term
Phenoxybenzamine, Phentolamine
-Drug class
-Application
-Special Notes |
|
Definition
Non-selective Alpha blocker
-pheochromocytoma
-phenoxybenzamine is irreversible --> prophylaxis prior to resection of tumor
- orthostatic hypotension, reflex tachycardia
-if epinephrine given get drop in BP (unopposed B2 effect) |
|
|
Term
Prazosin, Terazosin, Doxazosin
Class
Applications
Toxicity
Special Note |
|
Definition
-Selective Alpha 1 Blocker
-Hypertension, BPH-urinary retention
-First dose hypotension, dizziness, headache
-give first dose before bed |
|
|
Term
Tamsulosin
Class
Applications |
|
Definition
-selective alpha 1 blocker prostate specific
-urinary retention in BPH for pts. w/o HTN |
|
|
Term
Mirtazapine
-Class
-Application
-Toxicity |
|
Definition
selective Alpha 2 blocker
-depression, especially elderly
-sedation, hypercholesterolemia, orexigenic |
|
|
Term
Alpha 1 Receptor
-Major Functions
-G-Protein Class |
|
Definition
Vasoconstriction
Mydriasis (contracts iris dilator m.)
Intestinal sphincter contraction
Bladder sphincter contraction
Uses Gq
(HAVe 1 M&M)
PLC-PIP2-IP3/DAG-PKC
|
|
|
Term
Alpha 2 Receptor
Major Functions
Protein Class |
|
Definition
inhibitor of sympathetic outflow
vasodilation
decreases insulin release
Uses Gi
MAD 2's
(inhibits adenylyl cyclase->low cAMP, low PKA) |
|
|
Term
Beta 1 Receptor
Major functions
G protein class |
|
Definition
Increase heart rate and contractility
increase renin release
increase lipolysis
Uses Gs
(Adenylyl cyclase-cAMP-PKA) |
|
|
Term
Beta 2 Receptor
Major functions
G Protein Class |
|
Definition
Vasodilation
Bronchodilation
Uterine relaxation
Increases heart rate/contractility (reflexive)
Increases lipolysis and insulin release
Uses Gs
(Adenylyl cyclase-cAMP-PKA) |
|
|
Term
M1 Receptor
Major Functions
G Protein Class |
|
Definition
CNS-arousal, memory
Enteric Nervous system- ECL cells-histamine
Uses Gq
HAVe 1 M&M
PLC-PIP2-IP3/DAG-PKC |
|
|
Term
M2 Receptor
Major functions
G protein class |
|
Definition
Decrease heart rate and contractility (atria)
Uses Gi
(MAD 2's)
(Inhibits adenylyl cyclase- low cAMP- low PKA) |
|
|
Term
M3 Receptor
Major functions
G Protein Class |
|
Definition
Exocrine glands- increase secretion
Gut secretions and peristalsis
Bladder contraction
Bronchoconstriction
Miosis (contracts iris constrictor m.)
Accommodation (contracts ciliary m.)
Uses Gq
HAVe 1 M&M
(PLC-PIP2-IP3/DAG-PKC) |
|
|
Term
D1 Receptor
Major Functions
G Protein Class |
|
Definition
Renal vasodilation
Uses Gs
Adenylyl Cyclase- cAMP-PKA |
|
|
Term
D2 Receptor
Major Functions
G Protein Class |
|
Definition
Modulates neurotransmitter release in brain
Uses Gi
MAD 2's
(inhibits adenylyl cyclase- low cAMP, low PKA)
|
|
|
Term
H1 Receptor
Major functions
G Protein Class |
|
Definition
Respiratory mucus production
Bronchiolar constriction
Pruritus
Pain
Allergies!
Uses Gq
(HAVe 1 M&M)
(PLC-PIP2-IP3/DAG-PKC) |
|
|
Term
H2 Receptor
Major functions
G Protein Class |
|
Definition
Increases gastric acid secretion from parietal cells
Uses Gs
(Adenylyl Cyclase-cAMP-PKA) |
|
|
Term
V1
Major functions
GProtein Class |
|
Definition
vascoconstriction
Uses Gq
(HAVe 1 M&M)
PLC-PIP2-IP3/DAG-PKC |
|
|
Term
V2
Major Functions
GProtein Class |
|
Definition
Urine concentration/H20 resorption
(expression of resorption channels in collecting tubules of kidney)
(AQP2, NKCC2)
Uses Gs
Adenylyl cyclase- cAMP-PKA |
|
|
Term
Nadolol
Propranolol
Pindolol
Timolol
-Drug Class
-What's special about timoilol? Propranolol?
|
|
Definition
Non Selective Beta Blockers
(Block B1 and B2 equally)
-Timolol: Glaucoma (decreases secretion aqueous humor)
-Propranolol: SVT- class II antiarrhythmic
slows AV conduction velocity |
|
|
Term
Acetbutolol
Betaxolol
Esmolol
Atenolol
Metoprolol
Drug Class
Patient population
What's special about metoprolol? Esmolol?
|
|
Definition
Selective Beta 1 Blockers
A BEAM of Beta 1 Blockers
-Patients with comorbid pulmonary dz.
-Metoprolol reduces mortality after MI
-Esmolol: SVT short acting, IV, Class II antiarrhythmi
Slows AV conduction velocity
|
|
|
Term
Carvedilol
Labetalol
Drug Class
What's special about carvedilol? |
|
Definition
Non-Selective Alpha and Beta Blockers
Carvedilol reduces post-MI mortality |
|
|
Term
Beta Blockers
Applications
Toxicity
Specific Contraindications
|
|
Definition
App:
Hypertension: DOC for aortic dissection
Angina
Post-MI (metoprolol and carvedilol)
SVT (propranolol and esmolol)
Chronic/Stable CHF
Glaucoma (timolol)
TOX:
Impotence
Asthma exacerbation (use ABEAM of B1 selectives )
Bradycardia, AV block, CHF
CNS-sedation, altered sleep
Contraindications: Cocaine (unopposed alpha 1)
acebutolol, betaxolol, esmolol atenolol, metoprolol, propranolol, timolol, pindolol, labetolol |
|
|
Term
Volume of Distribution
Formula
Values and spaces |
|
Definition
Vd = amt. drug in body
Conc. in plasma
Low Vd- blood
Med Vd- ECF
High- all tissues (lipids) |
|
|
Term
|
Definition
CL= Vd (0.7)
t1/2
(rate of elimination/plasma concentration) |
|
|
Term
Half Life
Formula
Steady States |
|
Definition
t1/2=0.7 (Vd)
CL
4 half lives- 93.75%
(of Css reached OR eliminated from the body) |
|
|
Term
Loading Dose
Formula
Special Situations
|
|
Definition
LD=Cp x Vd
F
Affected by volume of distribution
Not altered by renal or liver disease
Bioavailability usually 1 |
|
|
Term
Maintenance Dose
Formula
Special situations |
|
Definition
MD=Cp x CL
F
Altered in renal or liver disease
Bioavailability usually 1
|
|
|
Term
|
Definition
A substrate concentration; reflects enzyme affinity for substrate
Higher Km, lower affinity
[S] at 1/2Vmax
Increased by competitive inhibitors
Relates to potency of a drug |
|
|
Term
|
Definition
Max rate of enzyme activity- saturation
Proportional to enzyme concentration
Lowered by non-competitive inhibitors
Related to a drug's efficacy |
|
|